IPHS 10Q 09.30.13
Table of Contents

 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 _______________________________________
FORM 10-Q
 ___________________________________________
(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2013
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from              to               .
Commission File Number 001-33124
 ___________________________________________
INNOPHOS HOLDINGS, INC.
(Exact Name of Registrant as Specified in its Charter)
 ___________________________________________
 
Delaware
 
20-1380758
(State or Other Jurisdiction of
Incorporation or Organization)
 
(I.R.S. Employer
Identification No.)
 
 
259 Prospect Plains Road
Cranbury, New Jersey
 
08512
(Address of Principal Executive Offices)
 
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (609) 495-2495
 ____________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “accelerated filer,” “large accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer
x
  
Accelerated Filer
o
Non-accelerated filer
o
  
Smaller reporting company
o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x
As of September 30, 2013, the registrant had 21,982,966 shares of common stock outstanding.
 


Table of Contents

TABLE OF CONTENTS
 
 
 
Page
 
 
 
 
 
Item 1.
Item 2.
Item 3.
Item 4.
 
 
 
 
 
 
 
 
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
 
 
 
 


Page 2 of 37



Table of Contents

PART I
 
ITEM 1.
FINANCIAL STATEMENTS
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited)
(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)
 
 
September 30,
2013
 
December 31,
2012
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
35,799

 
$
26,815

Accounts receivable, net
99,230

 
94,033

Inventories
157,933

 
162,941

Other current assets
78,322

 
99,927

Total current assets
371,284

 
383,716

Property, plant and equipment, net
201,646

 
195,723

Goodwill
83,879

 
83,879

Intangibles and other assets, net
73,332

 
75,948

Total assets
$
730,141

 
$
739,266

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Current liabilities:
 
 
 
Current portion of long-term debt
$
4,003

 
$
4,000

Accounts payable, trade and other
43,564

 
36,485

Other current liabilities
29,804

 
46,030

Total current liabilities
77,371

 
86,515

Long-term debt
158,007

 
172,000

Other long-term liabilities
35,396

 
36,428

Total liabilities
$
270,774

 
$
294,943

Commitments and contingencies (note 13)

 

Common stock, par value $.001 per share; authorized 100,000,000; issued 22,266,832 and 22,110,249; outstanding 21,982,966 and 21,830,870 shares
22

 
22

Paid-in capital
117,516

 
115,782

Common stock held in treasury, at cost (283,866 and 279,379 shares)
(12,481
)
 
(12,411
)
Retained earnings
358,742

 
346,866

Accumulated other comprehensive loss
(4,432
)
 
(5,936
)
Total stockholders' equity
459,367

 
444,323

Total liabilities and stockholders' equity
$
730,141

 
$
739,266


See notes to condensed consolidated financial statements

Page 3 of 37



Table of Contents

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Income (Unaudited)
(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)
 
 
Three months ended
 
Nine months ended
 
September 30,
2013
 
September 30,
2012
 
September 30,
2013
 
September 30,
2012
Net sales
$
219,993

 
$
211,188

 
$
647,610

 
$
653,620

Cost of goods sold
181,288

 
168,409

 
530,976

 
512,605

Gross profit
38,705

 
42,779

 
116,634

 
141,015

Operating expenses:
 
 
 
 
 
 
 
Selling, general and administrative
17,156

 
17,417

 
53,451

 
49,687

Research & development expenses
828

 
776

 
2,407

 
2,320

Total operating expenses
17,984

 
18,193

 
55,858

 
52,007

Operating income
20,721

 
24,586

 
60,776

 
89,008

Interest expense, net
1,709

 
1,314

 
4,455

 
4,536

Foreign exchange loss (gain)
674

 
(1,800
)
 
3,091

 
(2,199
)
Income before income taxes
18,338

 
25,072

 
53,230

 
86,671

Provision for income taxes
7,398

 
8,366

 
18,320

 
25,873

Net income
$
10,940

 
16,706

 
$
34,910

 
60,798

Net income attributable to participating common shareholders
$
10,924

 
$
16,695

 
$
34,856

 
$
60,758

Per share data (note 2):
 
 
 
 
 
 
 
Income per participating share:
 
 
 
 
 
 
 
Basic
$
0.50

 
$
0.77

 
$
1.59

 
$
2.79

Diluted
$
0.49

 
$
0.74

 
$
1.56

 
$
2.70

Weighted average participating shares outstanding:
 
 
 
 
 
 
 
Basic
21,947,948

 
21,807,013

 
21,932,814

 
21,804,415

Diluted
22,323,705

 
22,500,262

 
22,322,987

 
22,519,360

 
 
 
 
 
 
 
 
Other comprehensive income, net of tax:
 
 
 
 
 
 
 
Change in interest rate swaps, (net of tax ($213), $136, $700 and $312)
$
(347
)
 
$
221

 
$
1,142

 
$
509

Change in pension and post-retirement plans, (net of tax $4, $(18), $258 and $70)
6

 
(80
)
 
362

 
167

Other comprehensive income, net of tax
$
(341
)
 
$
141

 
$
1,504

 
$
676

Comprehensive income
$
10,599

 
$
16,847

 
$
36,414

 
$
61,474


See notes to condensed consolidated financial statements

Page 4 of 37



Table of Contents

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in thousands)
 
 
Nine months ended
 
September 30,
2013
 
September 30,
2012
Cash flows from operating activities
 
 
 
Net income
$
34,910

 
$
60,798

Adjustments to reconcile net income to net cash provided from operating activities:
 
 
 
Depreciation and amortization
27,794

 
32,118

Amortization of deferred financing charges
425

 
428

Deferred income tax provision (benefit)
610

 
(1,545
)
Share-based compensation
1,766

 
3,319

Changes in assets and liabilities:
 
 
 
(Increase) decrease in accounts receivable
(5,197
)
 
11,278

Decrease in inventories
5,008

 
17,508

Decrease (increase) in other current assets
17,211

 
(3,138
)
Increase in accounts payable
7,079

 
2,844

Decrease in other current liabilities
(16,226
)
 
(18,933
)
Changes in other long-term assets and liabilities
650

 
(3,884
)
Net cash provided from operating activities
74,030

 
100,793

Cash flows used for investing activities:
 
 
 
Capital expenditures
(30,333
)
 
(15,997
)
Acquisition of businesses, net of cash acquired

 
(27,093
)
Net cash used for investing activities
(30,333
)
 
(43,090
)
Cash flows used for financing activities:
 
 
 
Proceeds from exercise of options
500

 
381

Long-term debt borrowings
28,000

 
15,000

Long-term debt repayments
(42,000
)
 
(50,000
)
Excess tax benefits from exercise of stock options
1,877

 
2,681

Common stock repurchases
(70
)
 
(7,255
)
Dividends paid
(23,020
)
 
(17,181
)
Net cash used for financing activities
(34,713
)
 
(56,374
)
Net change in cash
8,984

 
1,329

Cash and cash equivalents at beginning of period
26,815

 
35,242

Cash and cash equivalents at end of period
$
35,799

 
$
36,571


See notes to condensed consolidated financial statements

Page 5 of 37



Table of Contents

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Statement of Stockholders’ Equity (Unaudited)
(Dollars and shares in thousands)
 
Number of
Common
Shares
 
Common
Stock
 
Retained
Earnings
 
Paid-in
Capital
 
Accumulated
Other
Comprehensive
Income/(Loss)
 
Total
Shareholders'
Equity
Balance, December 31, 2011
21,620

 
$
22

 
$
292,144

 
$
106,037

 
$
(4,995
)
 
$
393,208

Net income
 
 
 
 
74,190

 
 
 
 
 
74,190

Other comprehensive loss, (net of tax $643)
 
 
 
 
 
 
 
 
(941
)
 
(941
)
Proceeds from stock award exercises and issuances
340

 


 
 
 
(2,255
)
 
 
 
(2,255
)
Share-based compensation
 
 
 
 
 
 
1,912

 
 
 
1,912

Excess tax benefits from exercise of stock options
 
 
 
 
 
 
3,931

 
 
 
3,931

Common stock repurchases
(150
)
 
 
 
 
 
(7,254
)
 
 
 
(7,254
)
Treasury stock reissued for acquisition of business
21

 
 
 
 
 
1,000

 
 
 
1,000

Dividends declared
 
 
 
 
(19,468
)
 
 
 
 
 
(19,468
)
Balance, December 31, 2012
21,831

 
$
22

 
$
346,866

 
$
103,371

 
$
(5,936
)
 
$
444,323

Net income
 
 
 
 
34,910

 
 
 
 
 
34,910

Other comprehensive loss, (net of tax $958)
 
 
 
 
 
 
 
 
1,504

 
1,504

Proceeds from stock award exercises and issuances
156

 
 
 
 
 
(1,909
)
 
 
 
(1,909
)
Share-based compensation
 
 
 
 
 
 
1,766

 
 
 
1,766

Excess tax benefits from exercise of stock options
 
 
 
 
 
 
1,877

 
 
 
1,877

Restricted stock forfeitures
(4
)
 
 
 
 
 
(70
)
 
 
 
(70
)
Dividends declared
 
 
 
 
(23,034
)
 
 
 
 
 
(23,034
)
Balance, September 30, 2013
21,983

 
$
22

 
$
358,742

 
$
105,035

 
$
(4,432
)
 
$
459,367


See notes to condensed consolidated financial statements

Page 6 of 37



Table of Contents

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)

1. Basis of Statement Presentation
Summary of Significant Accounting Policies
The accompanying unaudited condensed consolidated financial statements of Innophos Holdings, Inc. and Subsidiaries, or Company, have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S.) for interim financial reporting and do not include all disclosures required by generally accepted accounting principles in the U.S. for annual financial reporting, and should be read in conjunction with the audited consolidated and combined financial statements of the Company at December 31, 2012 and for the three years then ended.
The accompanying unaudited condensed consolidated financial statements of the Company reflect all adjustments which management considers necessary for a fair statement of the results of operations for the interim periods and is subject to year-end adjustments. The results of operations for the interim periods are not necessarily indicative of the results for the full year. The December 31, 2012 condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S.
Certain prior year balances have been reclassified to conform to current year presentation.
Out of Period Adjustments
During the first quarter of fiscal 2013, we identified an adjustment necessary for a long-term supply contract. We corrected this item during the first quarter of fiscal 2013, which had the effect of increasing cost of goods sold by $2.3 million, and decreasing net income by $1.6 million for the nine month period ended September 30, 2013.. This prior period adjustment is not material to the financial results of the previously issued annual financial statements or current or previously issued interim financial statements. This adjustment is also not expected to be material to the full year 2013 financial statements.
Recently Issued Accounting Standards
Adopted
In January 2013, the Financial Accounting Standards Board, or FASB, issued a pronouncement updating the accounting for financial instruments, which clarifies the scope of disclosures about offsetting assets and liabilities. This pronouncement limits the scope of instruments subject to the offsetting disclosures to derivatives, repurchase and reverse repurchase agreements, and securities borrowing and lending agreements subject to master netting arrangements or similar agreements. This pronouncement is effective for annual and interim periods beginning on or after January 1, 2013. The adoption of this accounting pronouncement did not have a material impact on the Company's consolidated financial position and results of operations.
In February 2013, the FASB issued an amendment to the accounting guidance for the reporting of amounts reclassified out of accumulated other comprehensive income (“AOCI”). The amendment expands the existing disclosure by requiring entities to present information about significant items reclassified out of AOCI by component. In addition, an entity is required to provide information about the effects on net income of significant amounts reclassified out of each component of AOCI to net income either on the face of the statement where net income is presented or as a separate disclosure in the notes of the financial statements. The amendment is effective prospectively for annual or interim reporting periods beginning after December 15, 2012. The adoption of this accounting pronouncement did not have a material impact on the Company's consolidated financial position and results of operations.
In July 2013, the FASB issued amendments to allow the Federal Funds Effective Swap Rate (which is the Overnight Index Swap rate, or OIS rate, in the U.S.) to be designated as a benchmark interest rate for hedge accounting purposes under the derivatives and hedging guidance. The amendments also allow for the use of different benchmark rates for similar hedges. The amendments are effective prospectively for qualifying new or redesignated hedging relationships entered into on or after July 17, 2013. The initial adoption had no impact on our consolidated financial position and results of operation.
Issued but not yet adopted
In July 2013, the FASB issued amendments to guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The amendments require entities to present an unrecognized tax benefit netted against certain deferred tax assets when specific requirements are met. The

Page 7 of 37



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013 (early adoption is permitted). The Company is currently assessing the impact of the amended guidance on its consolidated financial position.


2. Earnings per share (EPS)
The Company accounts for earnings per share in accordance with ASC 260 and related guidance, which requires two calculations of earnings per share (EPS) to be disclosed: basic EPS and diluted EPS. Under ASC Subtopic 260-10-45, as of January 1, 2009 unvested awards of share-based payments with rights to receive dividends or dividend equivalents, such as our restricted stock, are considered participating securities for purposes of calculating EPS. Under the two-class method, a portion of net income is allocated to these participating securities and therefore is excluded from the calculation of EPS allocated to common stock, as shown in the table below.
The numerator for basic and diluted earnings per share is net earnings attributable to shareholders reduced by dividends attributable to unvested shares. The denominator for basic earnings per share is the weighted average number of common stock outstanding during the period. The denominator for diluted earnings per share is weighted average shares outstanding adjusted for the effect of dilutive outstanding stock options, performance share awards and restricted stock awards.
The following is a reconciliation of the weighted average basic number of common shares outstanding to the diluted number of common and common stock equivalent shares outstanding and the calculation of earnings per share using the two-class method:
 
 
Three Months Ended
 
Nine Months Ended
 
September 30, 2013
 
September 30, 2012
 
September 30, 2013
 
September 30, 2012
Net income
$
10,940

 
$
16,706

 
$
34,910

 
$
60,798

Less: earnings attributable to unvested shares
(16
)
 
(11
)
 
(54
)
 
(40
)
Net income available to participating common shareholders
$
10,924

 
$
16,695

 
$
34,856

 
$
60,758

Weighted average number of participating common and potential common shares outstanding:
 
 
 
 
 
 
 
Basic number of participating common shares outstanding
21,947,948

 
21,807,013

 
21,932,814

 
21,804,415

Dilutive effect of stock equivalents
375,757

 
693,249

 
390,173

 
714,945

Diluted number of weighted average participating common shares outstanding
22,323,705

 
22,500,262

 
22,322,987

 
22,519,360

Earnings per participating common share:
 
 
 
 
 
 
 
Earnings per participating common share—Basic
$
0.50

 
$
0.77

 
$
1.59

 
$
2.79

Earnings per participating common share—Diluted
$
0.49

 
$
0.74

 
$
1.56

 
$
2.70

 
 
 
 
 
 
 
 
Total outstanding options, performance share awards and unvested restricted stock not included in the calculation of diluted earnings per share as the effect would be anti-dilutive
396,952

 
387,878

 
382,503

 
366,182



Page 8 of 37



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


3. Dividends
The following is the dividend activity for the three and nine months ended September 30, 2013 and September 30, 2012: 
 
Three Months Ended
 
Nine Months Ended
 
September 30
 
September 30
 
2013
 
2012
 
2013
 
2012
Dividends declared – per share
$
0.35

 
$

 
$
1.05

 
$
0.54

Dividends declared – aggregate
7,694

 

 
23,020

 
11,776

Dividends paid – per share
0.35

 
0.27

 
1.05

 
0.79

Dividends paid – aggregate
7,694

 
5,891

 
23,020

 
17,181


We are a holding company that does not conduct any business operations of our own. As a result, we are dependent upon cash dividends, distributions and other transfers from our subsidiaries, most directly Innophos, Inc., our primary operating subsidiary, and Innophos Investments Holdings, Inc., its parent, to make dividend payments on our Common Stock. The Company's Board of Directors declared an increase to its quarterly dividend to $0.40 per share to be paid in the fourth quarter of 2013.


4. Stockholders’ Equity / Stock-Based Compensation
Our compensation programs include share-based payments. The primary share-based awards and their general terms and conditions currently in effect are as follows:
Stock options, which entitle the holder to purchase, after the end of a vesting term, a specified number of shares of the Company’s common stock at an exercise price per share set equal to the market price of the Company’s common stock on the date of grant.
Performance share awards which entitle the holder to receive, at the end of a vesting term, a number of shares of the Company’s common stock, within a range of shares from zero to a specified maximum (generally 200%), calculated using a combination of performance indicators as defined solely by reference to the Company’s own activities. Amounts equivalent to dividends will accrue over the performance period and are paid on performance share awards when vested and distributed.
Restricted stock grants, which entitle the holder to receive, at the end of each vesting term, a specified number of shares of the Company's common stock, and which also entitle the holder to receive dividends paid on such grants throughout the vesting period.
Annual stock retainer grants, which entitle independent members of the Board of Directors to receive a number of shares of the Company’s common stock equal to a fixed retainer value.
 
Restricted Stock
On March 29, 2013 there were a total of 25,853 restricted shares granted to certain employees with a fair value of $1.4 million. These awards are classified as equity awards and vest annually over three years. The related compensation expense is based on the date of grant share price of $54.59. The compensation expense is amortized on a straight-line basis over the requisite vesting period and accelerated for those employees that are retirement eligible during the vesting period.
Stock Options
On March 29, 2013 the Company granted 63,580 non-qualified stock options at an exercise price of $54.59 per share to certain employees with a fair value of $1.3 million. The non-qualified stock options vest annually over three years with a March 29, 2023 expiration date.

Page 9 of 37



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

The fair value of the options granted during 2013 was determined using the Black-Scholes option-pricing model. The assumptions used in the Black-Scholes option-pricing model were as follows:
 
Non-qualified stock options
 
Expected volatility
50.4
%
Dividend yield
2.8
%
Risk-free interest rate
1.0
%
Expected term (years)
6

Weighted average grant date fair value of stock options
$
19.99

For the 2013 grants the Company had chosen a blended volatility which consists of 50% historical volatility average of a peer group and 50% historical volatility of Innophos. The expected term for the stock options is based on the simplified method since the Company has limited data on the exercises of stock options. These stock options qualify as “plain vanilla” stock options in accordance with SAB 110. The dividend yield is the expected annual dividend payments divided by the average stock price up to the date of grant. The risk-free interest rates are derived from the U.S. Treasury securities in effect on the date of grant whose maturity period equals the options expected term. The Company applies an expected forfeiture rate to stock-based compensation expense. The estimate of the forfeiture rate is based primarily upon historical experience of employee turnover. As actual forfeitures become known, stock-based compensation expense is adjusted accordingly.
Performance Share Awards
On March 29, 2013, the Company granted 43,091 performance shares to certain employees with a fair value of $2.4 million. The performance shares vest at the end of the three year performance cycle and the number of shares distributable depends on the extent to which the Company attains pre-established performance goals. Amounts equivalent to declared dividends will accrue on the performance shares and will vest over the same period.
In connection with the vesting of the performance share awards issued in 2010, the Company issued 92,911 shares of common stock, net of minimum tax withholdings, to certain employees as required under the terms of the plan in the first quarter of 2013.
Stock Grants
In May 2013 the five external members of the Board of Directors were each granted 1,136 shares of the Company's common stock with an aggregated fair value of $0.3 million which immediately vested as part of their director fees.
The following table summarizes the components of stock-based compensation expense, all of which has been classified as selling, general and administrative expense:
 
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2013
 
September 30,
2012
 
September 30,
2013
 
September 30,
2012
Stock options
$
73

 
$
291

 
$
772

 
$
1,147

Restricted stock
169

 
57

 
517

 
180

Performance shares
(227
)
 
643

 
177

 
1,632

Stock grants

 

 
300

 
360

Total share-based compensation expense
$
15

 
$
991

 
$
1,766

 
$
3,319

 

Page 10 of 37



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


5. Inventories
Inventories consist of the following:
 
 
September 30,
2013
 
December 31,
2012
Raw materials
$
51,201

 
$
49,856

Finished products
96,231

 
103,563

Spare parts
10,501

 
9,522

 
$
157,933

 
$
162,941


Inventory reserves for excess quantities, obsolescence or shelf-life expiration as of September 30, 2013 and December 31, 2012 were $12,215 and $11,551, respectively.

6. Other Current Assets
Other current assets consist of the following:
 
 
September 30,
2013
 
December 31,
2012
Creditable taxes (value added taxes)
$
19,352

 
$
35,181

Vendor inventory deposits (prepaid)
21,481

 
19,445

Prepaid income taxes
22,750

 
22,000

Deferred income taxes
9,217

 
13,611

Other prepaids
3,312

 
2,884

Other
2,210

 
6,806

 
$
78,322

 
$
99,927


7. Depreciation and Amortization Expense
Depreciation expense has steadily declined from the assets acquired at the inception of Innophos on August 13, 2004. Approximately 70% of the depreciable assets from the inception of Innophos had a useful life of 6 to 10 years. The assets acquired after the inception of Innophos have become a much larger factor of depreciation expense and the useful lives assigned to these assets are generally longer. Please see the table below for additional analysis of that factor:
 
Nine months ended
 
 
 
 
 
September 30,
2013
 
2012
 
2011
Depreciation expense on fair value of assets in connection with the formation of Innophos on August 13, 2004
$
5,581

 
$
19,794

 
$
23,974

Amortization expense on fair value of intangibles in connection with the formation of Innophos on August 13, 2004
2,170

 
2,995

 
2,996

Depreciation expense from capital expenditures after 8/13/04
14,368

 
17,585

 
15,292

Acquisitions - depreciation expense
845

 
572

 
49

Acquisitions - intangible amortization expense
3,030

 
1,572

 
532

Changes in depreciation expense included in inventory
1,800

 
(184
)
 
833

Total
$
27,794

 
$
42,334

 
$
43,676


Page 11 of 37



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


8. Intangibles and Other Assets, net
Intangibles and other assets consist of the following:
 
 
Useful life
(years)
 
September 30,
2013
 
December 31,
2012
Developed technology and application patents, net of accumulated amortization of $18,295 for 2013 and $16,155 for 2012
7-20
 
$
26,185

 
$
28,325

Customer relationships, net of accumulated amortization of $9,611 for 2013 and $7,666 for 2012
5-15
 
27,439

 
29,384

Tradenames and license agreements, net of accumulated amortization of $5,854 for 2013 and $4,852 for 2012
5-20
 
11,596

 
12,598

Non-compete agreements, net of accumulated amortization of $757 for 2013 and $644 for 2012
4-10
 
553

 
666

Total intangibles
 
 
$
65,773

 
$
70,973

Deferred financing costs, net of accumulated amortization of $1,517 for 2013 and $1,092 for 2012 (see note 10)
 
 
$
2,142

 
$
2,567

Deferred income taxes
 
 
1,928

 

Other assets
 
 
3,489

 
2,408

Total other assets
 
 
$
7,559

 
$
4,975

 
 
 
$
73,332

 
$
75,948


Page 12 of 37



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


9. Other Current Liabilities
Other current liabilities consist of the following:
 
 
September 30,
2013
 
December 31,
2012
Payroll related
$
8,857

 
$
10,723

Freight and rebates
4,164

 
4,604

Benefits and pensions
6,195

 
6,727

Taxes other than income taxes
3,680

 
8,352

CNA water tax claims

 
10,855

Other
6,908

 
4,769

 
$
29,804

 
$
46,030


10. Short-term Borrowings, Long-Term Debt, and Interest Expense
Short-term borrowings and long-term debt consist of the following:
 
 
September 30,
2013
 
December 31,
2012
Term loan due 2017
$
97,000

 
$
100,000

Revolver borrowings under the credit facility
65,000

 
76,000

Capital leases
10

 

Total borrowings
$
162,010

 
$
176,000

Less current portion
4,003

 
4,000

Long-term debt
$
158,007

 
$
172,000


The Company's credit facility includes a term loan of $100.0 million and a revolving line of credit from the Lenders of up to $225.0 million, including a $20.0 million letter of credit sub-facility, all maturing on December 21, 2017. Repayments of the term loan are required at the rate of 1% of original principal amount per quarter beginning on March 31, 2013.
As of September 30, 2013, $97.0 million was outstanding under the Term Loan and $65.0 million was outstanding under the revolving line of credit, both of which approximate fair value because they have a floating interest rate, Level 2 input within the fair value hierarchy, with total availability at $157.7 million, taking into account $2.3 million in face amount of letters of credit issued under the sub-facility. The current weighted average interest rate for all debt is 2.4%.
Simultaneously with initiating the new senior facility, Innophos entered into an interest rate swap, swapping the LIBOR exposure on $100.0 million adjusting quarterly consistent with the Term Loan, with a fixed rate of 0.9475% plus the applicable margin on the debt expiring in December 2017. This interest rate swap has been designated as a cashflow hedge (Level 2) with the changes in value recorded through other comprehensive income. The fair value of this interest rate swap is an asset of approximately $0.8 million as of September 30, 2013.
We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status.
Total interest paid by the Company for all indebtedness for the nine months ended September 30, 2013 and September 30, 2012 was $3,429 and $4,355.
As of September 30, 2013, the Company was in full compliance with all debt covenant requirements.

Page 13 of 37



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


 
Interest expense, net consists of the following:
 
 
Three months ended
 
Nine months ended
 
September 30,
2013
 
September 30,
2012
 
September 30,
2013
 
September 30,
2012
Interest expense
$
1,664

 
1,371

 
$
4,280

 
4,350

Deferred financing cost
137

 
141

 
425

 
428

Interest income
(8
)
 
(11
)
 
(29
)
 
(55
)
Less: amount capitalized for capital projects
(84
)
 
(187
)
 
(221
)
 
(187
)
Total interest expense, net
$
1,709

 
$
1,314

 
$
4,455

 
$
4,536


11. Other Long-Term Liabilities
Other long-term liabilities consist of the following:
 
 
September 30,
2013
 
December 31,
2012
Deferred income taxes
$
20,337

 
$
21,497

Pension and post retirement liabilities (U.S. and Canada only)
7,254

 
7,253

Profit sharing and post employment liabilities
4,514

 
4,435

Environmental liabilities
1,100

 
1,100

Other liabilities
2,191

 
2,143

 
$
35,396

 
$
36,428


12. Income Taxes
The effective income tax rate on income before taxes was approximately 34% for the nine months ended September 30, 2013 compared to approximately 30% for the comparable period in 2012. The variance in the effective tax rate is primarily due to recording of uncertain income tax positions which increased the effective tax rate by 3% over the prior year and the Mexican CNA Water Tax Claims being recorded as discrete items for income tax provision purposes which increased the effective tax rate by 2% over the prior year.
The Company has recorded tax contingencies of $2.1 million, net of Federal benefit, for uncertain income tax positions in accordance with ASC 740-10-05-6. The Company’s policy is to accrue associated penalties in selling, general and administrative expenses and to accrue interest in net interest expense. Currently, the Company is under examination, or has been contacted for examination, by certain foreign jurisdictions for its income tax returns for the years 2006 through 2008. In 2011, our subsidiary, Innophos Mexicana requested a refund of $2.5 million for the 2009 tax year which was disputed by the Mexican tax authorities, however, in June of 2013, the Mexican courts ruled in the Company's favor. In addition, our subsidiary, Innophos Canada, Inc. was assessed approximately $4.0 million for the tax years 2006, 2007, and 2008 by the Canadian tax authorities. In April 2012, the Company filed a response to the Canadian tax authorities for the above tax matter disputing the full assessment and a follow up response on October 15, 2013. The Company believes that its tax position is more likely than not to be sustained and has not recorded a charge for this tax matter. On March 19, 2013, Internal Revenue Service commenced an examination of the Company's 2010 tax return. The company is also currently under audit in various other state tax jurisdictions for the years 2009 and 2010. Other than the assessments mentioned above, as of September 30, 2013, no material adjustments have been proposed to the Company's tax positions and the Company currently does not anticipate any adjustments that would result in a material change to its financial position during the next twelve months.
Income taxes paid were $21,723 and $36,931 for the nine months ended September 30, 2013 and September 30, 2012, respectively.

Page 14 of 37



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


13. Commitments and Contingencies
Environmental
The Company's operations are subject to extensive and changing federal and state environmental laws and regulations. The Company's manufacturing sites have an extended history of industrial use, and soil and groundwater contamination have or may have occurred in the past and might occur or be discovered in the future.
Environmental efforts are difficult to assess for numerous reasons, including the discovery of new remedial sites, discovery of new information and scarcity of reliable information pertaining to certain sites, improvements in technology, changes in environmental laws and regulations, numerous possible remedial techniques and solutions, difficulty in assessing the involvement of and the financial capability of other potentially responsible parties and the extended time periods over which remediation occurs. Other than the items listed below, the Company is not aware of material environmental liabilities which are probable and estimable. As the Company's environmental contingencies are more clearly determined, it is reasonably possible that amounts may need to be accrued. However, management does not believe, based on current information, that environmental remediation requirements will have a material impact on the Company's results of operations, financial position or cash flows.
Future environmental spending is probable at our site in Nashville, TN, the eastern portion of which had been used historically as a landfill, and a western parcel previously acquired from a third party, which reportedly had housed, but no longer does, a fertilizer and pesticide manufacturing facility. We have an estimated liability with a range of $0.9 million-$1.2 million. The remedial action plan for that site has yet to be finalized, and as such, the Company has recorded a liability, which represents the Company's best estimate, of $1.1 million as of September 30, 2013.
Litigation
2008 RCRA Civil Enforcement - Geismar, Louisiana plant
Following several inspections by the Environmental Protection Agency, or EPA, at our Geismar, LA purified phosphoric acid, or PPA, plant and related submissions we made to support claimed exemptions from the federal Resource, Conservation and Recovery Act, or RCRA, in March 2008, EPA referred our case to the Department of Justice, or DOJ, for civil enforcement. Although no citations were ever issued or formal proceedings instituted, the agencies claim we violate RCRA by failing to manage appropriately two materials that DOJ/EPA alleges are hazardous wastes. Those materials are: (i) Filter Material from an enclosed intermediate filtration step to further process green phosphoric acid we receive as raw material via pipeline from the adjacent site operated by an affiliate of Potash Corporation of Saskatchewan, or PCS; and (ii) Raffinate, a co-product we provide to PCS under a long-term contract we have with PCS.
Since referral of the case to DOJ, we and PCS have engaged in periodic discussions with DOJ/EPA and the Louisiana Department of Environmental Quality, or LDEQ, or collectively the Government Parties, in order to resolve the matter. In addition to asserting that the two materials in question are not hazardous wastes, we have also sought to demonstrate that both the nature and character of the materials as well as their use, handling and disposition were detailed in a solid waste permit amendment application filed in 1989 by PCS's predecessor, when our plant was first constructed, and approved by the LDEQ under the state RCRA program.
In the course of discussions with the Government Parties, the DOJ/EPA has required that we undertake, as an interim measure, the construction of a new filter unit that would replace the existing closed system and allow the removal and separate handling of the Filter Material. We built that unit, which is now in operation.
In an attempt to address the remaining concerns of the Government Parties, we and PCS undertook joint efforts to explore possible technical solutions to the issue of Raffinate treatment. Based upon work so far, there appears to be at least one technically viable approach, namely that of “deep well injection,” which we believe is acceptable to regulators as part of a negotiated solution among the parties.
Although we cannot give assurances as to the future course or ultimate outcome of ongoing negotiations, including whether litigation may ultimately ensue, we believe, based on our appreciation of the current state of the proceedings, that deep well injection is likely to be employed as the technologically acceptable approach for Raffinate and that we will not be asked to contribute substantially to the cost of the deep well to be specified by the Government Parties in an anticipated consent decree for settlement of this enforcement matter. However, in negotiated settlements leading to consent decrees with the Governmental Parties, it is also common for penalties relating to previous “non-compliance” to be assessed and, in that connection, we have

Page 15 of 37



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

been advised by the Governmental Parties that they expect to seek penalties against both PCS and us in this case. Although we have argued and made submissions to the effect that for purposes of settlement penalties there is no basis for any substantial penalty to be levied against us, nevertheless, we can give no assurance as to that outcome, or if a penalty is initially assessed as to its amount, or whether it will be necessary for us to oppose or seek indemnity for the assessment by further litigation. As a result, we have concluded that the contingent liability arising from compliance costs in this matter remains, as we have previously disclosed, neither remote nor probable, but reasonably possible.
Other Legal Matters
In March 2008, Sudamfos S.A., or Sudamfos, an Argentine phosphate producer, filed an arbitration before the ICC International Court of Arbitration, Paris, France, concerning an alleged agreement for our Mexicana subsidiary, Mexicana, to sell it 12,500 metric tons of phosphoric acid, but subsequently withdrew the proceeding. In October 2008, Mexicana filed suit in Mexico against Sudamfos to collect approximately $1.2 million representing the contract price for prior deliveries of acid for which Sudamfos had refused to pay. In October 2009, Sudamfos answered the suit and counterclaimed for $3.0 million based upon the agreement originally alleged in the arbitration. In subsequent proceedings including available appeals, Mexicana's claim was sustained and Sudamfos' counterclaim was denied. Mexicana has now begun formal collection proceedings against Sudamfos.
Innophos, Inc. has been assessed approximately $1.2 million of sales/use taxes by the State of Louisiana and Ascension Parish. This tax assessment covers certain raw materials used in the production of Phosphoric Acid. The Company is contesting both tax assessments. This assessment covers periods 2004 to 2010 for the Parish and 2007 to 2010 for the State. We have concluded that the contingent liability arising from this matter is neither remote nor probable, but reasonably possible.
In addition, we are party to legal proceedings and contractual disputes that arise in the ordinary course of our business. Except as to the matters specifically discussed, management believes that these matters represent remote liabilities. However, these matters cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, results of operations, financial condition, and/or cash flows.


Page 16 of 37



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

14. Pension Plans and Postretirement Benefits

Net periodic benefit expense for the United States plans:

For the three months ended September 30, 2013
 
For the three months ended September 30, 2012
 
Pension benefits
 
Other benefits
 
Total
 
Pension benefits
 
Other benefits
 
Total
Service cost
$

 
$
91

 
$
91

 
$

 
$
81

 
$
81

Interest cost
27

 
40

 
67

 
28

 
34

 
62

Expected return on assets
(27
)
 

 
(27
)
 
(28
)
 

 
(28
)
Amortization of
 
 
 
 
 
 
 
 
 
 
 
prior service cost

 

 

 

 
33

 
33

unrecognized (gain) loss
14

 

 
14

 
4

 
(7
)
 
(3
)
Net periodic cost
$
14

 
$
131

 
$
145

 
$
4

 
$
141

 
$
145

 
 
 
 
 
 
 
 
 
 
 
 
 
For the nine months ended September 30, 2013
 
For the nine months ended September 30, 2012
 
Pension benefits
 
Other benefits
 
Total
 
Pension benefits
 
Other benefits
 
Total
Service cost
$

 
$
273

 
$
273

 
$

162,000

$
243

 
$
243

Interest cost
81

 
121

 
202

 
82

72,000

106

 
188

Expected return on assets
(82
)
 

 
(82
)
 
(82
)


 
(82
)
Amortization of
 
 
 
 
 
 
 
 
 
 
 
prior service cost

 

 

 

 
97

 
97

unrecognized (gain) loss
42

 

 
42

 
10

 
(21
)
 
(11
)
Net periodic cost
$
41

 
$
394

 
$
435

 
$
10

 
$
425

 
$
435


In April 2013, Innophos contributed approximately $0.1 million to its U.S. defined benefit pension plan to satisfy the full year 2013 minimum contribution requirements.
Innophos made its entire cash contribution of $2.9 million for the U.S. defined contribution plan during the first quarter of 2013 for the plan year 2012.


Page 17 of 37



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Net periodic benefit expense for the Canadian plans:
 
For the three months ended September 30, 2013
 
For the three months ended September 30, 2012
 
Pension benefits
 
Other benefits
 
Total
 
Pension benefits
 
Other benefits
 
Total
Service cost
$
86

 
$
19

 
$
105

 
$
85

 
$
21

 
$
106

Interest cost
138

 
20

 
158

 
151

 
26

 
177

Expected return on assets
(223
)
 

 
(223
)
 
(236
)
 

 
(236
)
Amortization of
 
 
 
 
 
 
 
 
 
 
 
actuarial loss (gain)
78

 
9

 
87

 
65

 
11

 
76

prior service cost
25

 

 
25

 
26

 

 
26

net transition obligation

 
8

 
8

 

 
7

 
7

Exchange rate changes
(18
)
 
4

 
(14
)
 
122

 
22

 
144

Net periodic cost
$
86

 
$
60

 
$
146

 
$
213

 
$
87

 
$
300

 
 
 
 
 
 
 
 
 
 
 
 
 
For the nine months ended September 30, 2013
 
For the nine months ended September 30, 2012
 
Pension benefits
 
Other benefits
 
Total
 
Pension benefits
 
Other benefits
 
Total
Service cost
$
263

 
$
58

 
$
321

 
$
253

 
$
61

 
$
314

Interest cost
420

 
61

 
481

 
451

 
74

 
525

Expected return on assets
(679
)
 

 
(679
)
 
(706
)
 

 
(706
)
Amortization of
 
 
 
 
 
 
 
 
 
 
 
actuarial loss (gain)
238

 
27

 
265

 
195

 
35

 
230

prior service cost
76

 

 
76

 
78

 

 
78

net transition obligation

 
23

 
23

 

 
23

 
23

Exchange rate changes
186

 
(43
)
 
143

 
142

 
29

 
171

Net periodic cost
$
504

 
$
126

 
$
630

 
$
413

 
$
222

 
$
635

Innophos Canada, Inc. made cash contributions to its Canadian defined benefit plan of $0.6 million during the nine months ended September 30, 2013. Innophos Canada, Inc. plans to make additional cash contributions to its Canadian defined benefit plan of approximately $0.2 million during the remainder of 2013.


15. Segment Reporting
The company discloses certain financial and supplementary information about its reportable segments, revenue by products and revenues by geographic area. Operating segments are defined as components of an enterprise about which separate discrete financial information is evaluated regularly by the chief operating decision maker, in order to decide how to allocate resources and assess performance. The primary performance indicators for the chief operating decision maker are sales and operating income, with sales on a ship-from basis. All references to sales in this Form 10-Q, either on a ship-from or ship-to basis, are on the same basis of revenue recognition and are recognized when title and risk of loss passes to the customer, which occurs either upon shipment or delivery, depending upon the agreed sales terms with customers.
The Company's reportable segments reflect the core businesses in which Innophos operates and how it is managed. The Company reports its core specialty phosphates business separately from granular triple super-phosphate, or GTSP, and other non-specialty phosphate products (GTSP & Other). Kelatron, AMT and Triarco are included in the Specialty Phosphates US & Canada segment and in the Specialty Ingredients product line. Specialty Phosphates consists of the products lines Specialty Ingredients, Food & Technical Grade PPA, and STPP & Detergent Grade PPA. GTSP & Other includes fertilizer co-product GTSP and other non-specialty phosphate products.


Page 18 of 37



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

For the three months ended September 30, 2013
 
Specialty
Phosphates
US & Canada
 
Specialty
Phosphates
Mexico
 
GTSP &
Other
 
Eliminations
 
Total
Sales
 
$
153,588



$
44,712


$
21,693


$


$
219,993

Intersegment sales
 
720



16,972




(17,692
)


Total sales
 
$
154,308



$
61,684


$
21,693


$
(17,692
)

$
219,993

Operating income
 
$
21,482



$
2,964


$
(3,725
)

$


$
20,721

Depreciation and amortization expense
 
$
6,967



$
1,740


$
236


$


$
8,943

 
 
 
 
 
 
 
 
 
 
 
For the three months ended September 30, 2012
 
Specialty
Phosphates
US & Canada
 
Specialty
Phosphates
Mexico
 
GTSP &
Other
 
Eliminations
 
Total
Sales
 
$
144,664

 
$
41,222

 
$
25,302

 
$

 
$
211,188

Intersegment sales
 
370

 
14,087

 
57

 
(14,514
)
 

Total sales
 
$
145,034

 
$
55,309

 
$
25,359

 
$
(14,514
)
 
$
211,188

Operating income
 
$
22,759

 
$
2,369

 
$
(542
)
 
$

 
$
24,586

Depreciation and amortization expense
 
$
5,732

 
$
3,670

 
$
1,160

 
$

 
$
10,562

 
 
 
 
 
 
 
 
 
 
 
For the nine months ended September 30, 2013
 
Specialty
Phosphates
US & Canada
 
Specialty
Phosphates
Mexico
 
GTSP &
Other
 
Eliminations
 
Total
Sales
 
$
463,633

 
$
126,997

 
$
56,980

 
$

 
$
647,610

Intersegment sales
 
2,021

 
44,095

 
239

 
(46,355
)
 

Total sales
 
$
465,654


$
171,092

 
$
57,219

 
$
(46,355
)
 
$
647,610

Operating income (a) (b)
 
$
56,032

 
$
4,954

 
$
(210
)
 
$

 
$
60,776

Depreciation and amortization expense
 
$
20,540

 
$
5,815

 
$
1,439

 
$

 
$
27,794

 
 
 
 
 
 
 
 
 
 
 
For the nine months ended September 30, 2012
 
Specialty
Phosphates
US & Canada
 
Specialty
Phosphates
Mexico
 
GTSP &
Other
 
Eliminations
 
Total
Sales
 
$
432,528

 
$
139,951

 
$
81,141

 
$

 
$
653,620

Intersegment sales
 
1,218

 
45,082

 
320

 
(46,620
)
 

Total sales
 
$
433,746

 
$
185,033

 
$
81,461

 
$
(46,620
)
 
$
653,620

Operating income (a) (b)
 
$
70,262

 
$
17,156

 
$
1,590

 
$

 
$
89,008

Depreciation and amortization expense
 
$
17,280

 
$
11,233

 
$
3,605

 
$

 
$
32,118

 
 
 
 
 
 
 
 
 
 
 

(a)
The nine month period ended September 30, 2013 includes a $7.2 million benefit to earnings for the settlement of the Mexican CNA Water Tax Claims. The nine months ended September 30, 2012 includes a $7.1 million benefit to earnings related to updates to the provision for the CNA Fresh Water Claims in GTSP & Other.
(b)
The nine month period ended September 30, 2013 includes a $2.3 million charge to earnings for out of period costs in the US. The nine months ended September 30, 2012 includes a $2.4 million of out of period cost in Mexico in GTSP & Other.

Page 19 of 37



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


16. Acquisitions
In July 2012, Innophos purchased AMT Labs, Inc. and an affiliated company holding real property. The purchase accounting for the acquisition was closed in the first quarter of 2013 and no adjustments were recognized.
In December 2012, Innophos acquired the assets of Triarco Industries, Inc. ("Triarco"). Triarco, a privately held company based in New Jersey, has been manufacturing high quality custom ingredients for the food, beverage and dietary supplement industries for more than 30 years. Triarco specializes in botanical and enzyme based ingredients that provide important nutritional benefits and are often formulated with bioactive minerals and specialty phosphates. In the transaction, an Innophos subsidiary purchased all of Triarco's assets for $44.1 million in cash plus $1 million in shares of Innophos Holdings, Inc. Common Stock. The preliminary allocation of the purchase price of the acquisition has currently been included in these financial statements and changes to that allocation may occur as additional information becomes available. An additional fair value adjustment decreasing inventory (and increasing goodwill) by approximately $0.7 million was recognized in the period ended March 31, 2013. This fair value adjustment has been reclassified on the December 31, 2012 balance sheet.

17. Subsequent Events
On October 17, 2013, Innophos Acquisition II (an indirect subsidiary of Innophos, Inc.) acquired substantially all of the assets of privately held Chelated Minerals International, Inc., (CMI), based in Salt Lake City, Utah. CMI has significant knowhow in the manufacture and science of chelated minerals supplied to the human nutrition market. The acquisition of CMI strengthens Innophos’ position in micronutrient ingredients, which further enhances the Company’s ability to supply a broad range of nutrition fortification solutions to its customers. Innophos enjoys a strong position in macronutrient minerals such as calcium, magnesium and potassium that are required in relatively large amounts for a balanced diet. The human diet also requires smaller quantities of a wide range of other minerals such as chromium, selenium, zinc and iron classified as micronutrients.
The acquisition had a purchase price of $5 million, subject to specified adjustments, and was funded from cash on-hand.


Page 20 of 37



Table of Contents

ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This discussion contains forward-looking statements about our markets, the demand for our products and services and our future results. We based these statements on assumptions that we consider reasonable. Actual results may differ materially from those suggested by our forward-looking statements for various reasons including those discussed in the “Risk Factors” and “Forward-Looking Statements” sections of this report.
Innophos is a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. Innophos combines more than a century of experience in specialty phosphate manufacturing with a growing capability in a broad range of other specialty ingredients to supply a product range produced to stringent regulatory manufacturing standards and the quality demanded by customers worldwide. Many of Innophos' products are application-specific compounds engineered to meet customer performance requirements and are often critical to the taste, texture and performance of foods, beverages, pharmaceuticals, oral care products and other applications. For example, Innophos products act as flavor enhancers in beverages, electrolytes in sports drinks, texture additives in cheeses, leavening agents in baked goods, pharmaceutical excipients, cleaning agents in toothpaste and provide a wide range of nutritional fortification solutions for food, beverage and nutritional supplement manufacturers.

Page 21 of 37



Table of Contents


Recent Trends and Outlook
Moderate market demand growth continued for Specialty Phosphates in the third quarter 2013. The continued success of our growth strategy, targeted to achieve 2-3% above the market rate overall, resulted in 3% year-over-year core business growth for Specialty Phosphates. Export sales were up 16% year-over-year and reached their highest level since first quarter 2012. Overall, Specialty Phosphates volume growth was 7% with 4% coming from acquisitions.
Our fourth quarter 2013 Specialty Phosphates year-over-year growth expectation is flat, excluding the benefit of the Triarco acquisition, as expected growth for the US & Canada business should be offset by a decline in the Mexico business. Mexico’s fourth quarter 2013 Specialty Phosphates volumes overall are expected to increase by 8-10% compared to the prior year; however, intercompany sales to replenish US inventories that were depleted throughout the year are expected to be double the year ago levels, which will result in a year-over-year decrease of trade sales in the Latin American region. The benefit of the Triarco acquisition made at the end of 2012 is expected to contribute an additional 3% revenue growth during the fourth quarter 2013 in comparison to the prior year period.
Market prices for key raw materials, phosphate rock and sulfur, both declined during the third quarter 2013, with sulfur showing the most notable drop of approximately one-third from its second quarter 2013 level. Lower purchase prices achieved in the third quarter are expected to be realized in the fourth quarter 2013 income statement, providing approximately 100 basis points of additional Specialty Phosphates operating income margin.
Specialty Phosphates operating income margins were 12% for the third quarter 2013, below original expectations, primarily due to US/Canada business mix and approximately $2 million higher costs than expected for the planned maintenance outage in Coatzacoalcos. Total costs incurred for the third quarter 2013 planned maintenance outage were approximately $4.5 million, with approximately $3.5 million recorded in Specialty Phosphates and approximately $1.0 million recorded in GTSP & Other. The benefit of these costs not recurring in the fourth quarter 2013 will be partially offset by lower cost leverage from the effects of seasonal volume declines for the business. Combined with the noted raw material cost savings, Specialty Phosphates operating income margin is expected to improve to approximately 14% for the fourth quarter 2013.
GTSP & Other profitability slipped to a $4 million operating loss for the third quarter 2013 due to a 15-20% decline in fertilizer prices caused by broad-based decline in market demand. The rapid decline in selling prices required an approximate $2 million lower of cost or market adjustment on the ending inventory levels, resulting in a greater operating loss for the quarter. Market prices are expected to fall further due to seasonally lower market demand, so our expectation is for a similar operating loss in the fourth quarter as just experienced in the third quarter 2013. Once market prices level off and allow for raw material costs to catch-up, operating income is expected to return close to break-even.
Net debt (total long-term debt (including any current portion) less cash and cash equivalents) decreased sequentially by $10 million in the third quarter 2013 to $126 million as a result of progress made on recovering tax refunds from the Mexican government. Gross debt was reduced by $6 million reflecting payments made against the credit facility during the third quarter 2013.
Looking ahead to 2014, our preliminary indication for Specialty Phosphates volume growth is in the 3-5% range. This is down slightly from previous targets, as we now see market demand growing at 1-2% rather than 2-3%, offset by continued success in executing our growth initiatives to deliver above market growth rates. Specialty Phosphates operating income margins are expected to be in the 14-15% range, and GTSP & Other is expected to return to the more recent norms of break-even.


 

Page 22 of 37



Table of Contents


Historical Performance
Results of Operations
The following table sets forth a summary of the Company’s operations and their percentages of total revenue for the periods indicated. (dollars in millions):
 
 
Three Months Ended
 
Three Months Ended
 
September 30, 2013
 
September 30, 2012
 
Amount
 
%
 
Amount
 
%
Net sales
$
220.0

 
100.0

 
$
211.2

 
100.0

Cost of goods sold
181.3

 
82.4

 
168.4

 
79.7

Gross profit
38.7

 
17.6

 
42.8

 
20.3

Operating expenses:
 
 
 
 
 
 
 
Selling, general and administrative
17.2

 
7.8

 
17.4

 
8.2

Research & development
0.8

 
0.4

 
0.8

 
0.4

Income from operations
20.7

 
9.4

 
24.6

 
11.6

Interest expense, net
1.7

 
0.8

 
1.3

 
0.6

Foreign exchange losses (gains), net
0.7

 
0.3

 
(1.8
)
 
(0.9
)
Provision for income taxes
7.4

 
3.4

 
8.4

 
4.0

Net income
$
10.9

 
5.0

 
$
16.7

 
7.9


 
Nine Months Ended
 
Nine Months Ended
 
September 30, 2013
 
September 30, 2012
 
Amount
 
%
 
Amount
 
%
Net sales
$
647.6

 
100.0

 
$
653.6

 
100.0

Cost of goods sold
531.0

 
82.0

 
512.6

 
78.4

Gross profit
116.6

 
18.0

 
141.0

 
21.6

Operating expenses:
 
 
 
 
 
 
 
Selling, general and administrative
53.4

 
8.2

 
49.7

 
7.6

Research & development
2.4

 
0.4

 
2.3

 
0.4

Income from operations
60.8

 
9.4

 
89.0

 
13.6

Interest expense, net
4.5

 
0.7

 
4.5

 
0.7

Foreign exchange losses (gains), net
3.1

 
0.5

 
(2.2
)
 
(0.3
)
Provision for income taxes
18.3

 
2.8

 
25.9

 
4.0

Net income
$
34.9

 
5.4

 
$
60.8

 
9.3



Three months ended September 30, 2013 compared to the three months ended September 30, 2012
Net Sales
Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items invoiced to customers. Net sales for the three months ended September 30, 2013 were $220.0 million, an increase of $8.8 million, or 4.2%, as compared to $211.2 million for the same period in 2012. Higher sales in Specialty Phosphates resulting from acquisition benefits, growth in the US/Canada core business and improved operations in Mexico offset lower sales in GTSP & Other. Specialty Phosphates volumes were 7.2% higher, with acquisition benefits accounting for 4.1% of the increase and the core business contributing 3.1% growth, while selling prices were down 0.5%, primarily due to US/Canada sales mix. GTSP & Other volumes declined 3.3% and selling prices were down 11% versus the year ago period due to declining fertilizer market prices that ended 15-20% below where the quarter began.
The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to date period volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix.

Page 23 of 37



Table of Contents

The following table illustrates for the three months ended September 30, 2013 the percentage changes in net sales by reportable segment compared with the same period of the prior year, including the effect of price and volume/mix changes upon revenue:
 
 
Price
 
Volume/Mix
 
Total
Specialty Phosphates US & Canada
(1.5
)%
 
7.7
 %
 
6.2
 %
Specialty Phosphates Mexico
3.3
 %
 
5.2
 %
 
8.5
 %
Total Specialty Phosphates
(0.5
)%
 
7.2
 %
 
6.7
 %
GTSP & Other
(11.0
)%
 
(3.3
)%
 
(14.3
)%
Total
(1.7
)%
 
5.9
 %
 
4.2
 %
Note: Included within Specialty Phosphates US & Canada and Total Specialty Phosphates volume/mix variances were benefits of 5.3% and 4.1%, respectively, from the AMT business acquired in the third quarter of 2012 and the Triarco business acquired in December 2012.
The following table illustrates for the three months ended September 30, 2013 the percentage changes for net sales by Specialty Phosphates product lines compared with the prior year, including the effect of price and volume/mix changes:
 
 
Price
 
Volume/Mix
 
Total
Specialty Ingredients
(1.6
)%
 
12.1
 %
 
10.5
 %
Food & Technical Grade PPA
(1.5
)%
 
1.6
 %
 
0.1
 %
STPP & Detergent Grade PPA
8.1
 %
 
(12.8
)%
 
(4.7
)%
Note: Included within Specialty Ingredients volume/mix variance was a 5.9% benefit from the AMT business acquired in the third quarter of 2012 and the Triarco business acquired in December 2012.

Gross Profit
Gross profit represents net sales less cost of goods sold. Gross profit for the three months ended September 30, 2013 was $38.7 million, a decrease of $4.1 million, or 9.6%, as compared to $42.8 million for the same period in 2012. Gross profit percentage decreased to 17.6% for the three months ended September 30, 2013 versus 20.3% for the same period in 2012. Gross profit in 2013 was unfavorably affected by $3.7 million for lower selling prices, primarily due to GTSP & Other, $3.5 million increased manufacturing costs including changes in inventories, a net $2.8 million increase planned maintenance outage expenses mainly at our Coatzacoalcos manufacturing facility, and a $1.6 million lower of cost or market reserve recorded in the current period for GTSP. These unfavorable effects were partially offset by $2.1 million lower depreciation, $2.9 million favorable sales volume effects, $1.2 million benefit from acquisitions, and $0.7 million in lower raw material costs. Included in 2012 was $0.6 million for acquisition related fair value adjustments.
Operating Expenses and Research and Development
Operating expenses consist primarily of selling, general and administrative and research and development expenses. Operating expenses for the three months ended September 30, 2013 were $18.0 million, a decrease of $0.2 million, or 1.1%, as compared to $18.2 million for the same period in 2012.
Operating Income
Operating income for the three months ended September 30, 2013 was $20.7 million, a decrease of $3.9 million, or 15.9%, as compared to $24.6 million for the same period in 2012. Operating income as a percentage of net sales decreased to 9.4% versus 11.6% for the same period in 2012, for the reasons noted above.
Interest Expense, net
Net interest expense, including deferred financing amortization expense, for the three months ended September 30, 2013 was $1.7 million, an increase of $0.4 million due to the recording of interest expense on uncertain tax positions, or 30.8% as compared to $1.3 million for the same period in 2012.

Page 24 of 37



Table of Contents


Foreign Exchange
Foreign exchange for the three months ended September 30, 2013 was a loss of $0.7 million as compared to a gain of $1.8 million for the same period in 2012 that primarily resulted from a strengthening of the peso against the U.S. Dollar during the prior year period. The U.S. Dollar is the functional currency of our Mexican and Canadian operations. Consequently, foreign exchange gain or loss is recorded on remeasurement of non-U.S. dollar denominated monetary assets and liabilities. Such gains and losses fluctuate from period to period as the foreign currencies strengthen or weaken against the U.S. dollar and the amount of non-U.S. dollar denominated assets and liabilities increases or decreases.
Provision for Income Taxes
The effective income tax rate was 40% for the three months ended September 30, 2013 compared to 33% for the same period in 2012. The variance in the effective tax rate is due to the recording of uncertain income tax provisions which increased the tax rate by 7% over the prior year.
Net Income
Net income for the three months ended September 30, 2013 was $10.9 million, a decrease of $5.8 million as compared to $16.7 million for the same period in 2012, due to the factors described above.

Nine months ended September 30, 2013 compared to the nine months ended September 30, 2012
Net Sales
Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items invoiced to customers. Net sales for the nine months ended September 30, 2013 were $647.6 million, a decrease of $6.0 million, or 0.9%, as compared to $653.6 million for the same period in 2012. The decrease was primarily due to lower GTSP & Other sales which had 24.2% lower volumes and 5.6% lower prices due to soft fertilizer market conditions. Specialty Phosphates volumes were 4.5% higher, with a 4.9% benefit from acquisitions and a net 0.4% decline in our core business primarily resulting from first half 2013 operating issues in Mexico. Specialty Phosphates average selling prices were down 1.3% primarily due to unfavorable sales mix in the US/Canada business and a price reset on a long-term contract in Mexico.
The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to date period volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix. The following table illustrates for the nine months ended September 30, 2013 the percentage changes in net sales by reportable segment compared with the same period of the prior year, including the effect of price and volume/mix changes upon revenue:
 
 
Price
 
Volume/Mix
 
Total
Specialty Phosphates US & Canada
(1.1
)%
 
8.3
 %
 
7.2
 %
Specialty Phosphates Mexico
(2.0
)%
 
(7.3
)%
 
(9.3
)%
Total Specialty Phosphates
(1.3
)%
 
4.5
 %
 
3.2
 %
GTSP & Other
(5.6
)%
 
(24.2
)%
 
(29.8
)%
Total
(1.8
)%
 
0.9
 %
 
(0.9
)%
Note: Included within Specialty Phosphates US & Canada and Total Specialty Phosphates volume/mix variances were benefits of 6.5% and 4.9%, respectively, from the AMT business acquired in the third quarter of 2012 and the Triarco business acquired in December 2012.

Page 25 of 37



Table of Contents


The following table illustrates for the nine months ended September 30, 2013 the percentage changes for net sales by Specialty Phosphates product lines compared with the prior year, including the effect of price and volume/mix changes:
 
 
Price
 
Volume/Mix
 
Total
Specialty Ingredients
(2.2
)%
 
9.4
 %
 
7.2
 %
Food & Technical Grade PPA
0.4
 %
 
(1.2
)%
 
(0.8
)%
STPP & Detergent Grade PPA
1.3
 %
 
(15.2
)%
 
(13.9
)%
Note: Included within Specialty Ingredients volume/mix variance was a 7.0% benefit from the AMT business acquired in the third quarter of 2012 and the Triarco business acquired in December 2012.

Gross Profit
Gross profit represents net sales less cost of goods sold. Gross profit for the nine months ended September 30, 2013 was $116.6 million, a decrease of $24.4 million, or 17.3%, as compared to $141.0 million for the same period in 2012. Gross profit percentage decreased to 18.0% for the nine months ended September 30, 2012 versus 21.6% for the same period in 2012.
Gross profit in 2013 was unfavorably affected by $11.9 million for lower selling prices, $0.8 million higher raw material costs, $6.7 million higher fixed costs including change in inventory effects, a net $2.8 million increase in expenses for planned maintenance outages, mainly at our Coatzacoalcos manufacturing facility, a $1.6 million lower of cost or market reserve recorded in the current period for GTSP, $1.3 million unfavorable exchange rate mostly from Mexican peso based costs, and $15.4 million in elevated cost of goods sold for the first half 2013, of which $7.9 million related to Mexico manufacturing issues, $2.1 million related to a revision of estimates for phosphate rock inventories in Mexico, $2.3 million related to an out of period adjustment related to a long term supply agreement, $2.4 million related to demurrage on raw material purchases and other inventory related costs, and $0.7 million related to acquisition related fair value adjustments. The $40.5 million total of unfavorable effects were partially offset by $6.2 million benefit from acquisitions, $4.0 million for lower depreciation, $2.9 million higher sales volumes, and $2.4 million of expense in the second quarter 2012 for adjustments made to cost of goods sold, including amounts for prior periods. Included in 2012 was $0.6 million for acquisition related fair value adjustments. Both periods included a benefit of approximately $7 million as we made progress in reducing the amounts required to be paid to settle historical water duty claims by the Mexican authorities.
Operating Expenses and Research and Development
Operating expenses consist primarily of selling, general and administrative and research and development expenses. Operating expenses for the nine months ended September 30, 2013 were $55.8 million, an increase of $3.8 million, or 7.3%, as compared to $52.0 million for the same period in 2012. The increase was primarily due to the acquired AMT and Triarco businesses and an elevated focus on our quality and business process improvement programs partially offset by lower incentive compensation plan expenses.
Operating Income
Operating income for the nine months ended September 30, 2013 was $60.8 million, a decrease of $28.2 million, or 31.7%, as compared to $89.0 million for the same period in 2012. Operating income as a percentage of net sales decreased to 9.4% versus 13.6% for the same period in 2012, for the reasons noted above.
Interest Expense, net
Net interest expense, including deferred financing amortization expense, for the nine months ended September 30, 2013 was $4.5 million, no change when compared to $4.5 million for the same period in 2012, with 2013 benefits from lower interest rates on the new credit facility offset by $0.4 million of interest expense on uncertain tax positions recorded in the third quarter 2013.
Foreign Exchange
Foreign exchange for the nine months ended September 30, 2013 was a loss of $3.1 million as compared to a gain of $2.2 million for the same period in 2012, primarily due to weakening of the peso against the U.S. Dollar combined with higher monetary asset positions in the 2013 period versus a strengthening of the peso against the U.S. Dollar in the 2012 period. The U.S. Dollar is the functional currency of our Mexican and Canadian operations. Consequently, foreign exchange gain or loss is recorded on remeasurement of non-U.S. dollar denominated monetary assets and liabilities. Such gains and losses fluctuate

Page 26 of 37



Table of Contents

from period to period as the foreign currencies strengthen or weaken against the U.S. dollar and the amount of non-U.S. dollar denominated assets and liabilities increases or decreases.

Page 27 of 37



Table of Contents


Provision for Income Taxes
The effective income tax rate was 34% for the nine months ended September 30, 2013 compared to 30% for the same period in 2012. The variance in the effective tax rate is primarily due to recording of uncertain income tax positions which increased the effective tax rate by 3% over the prior year and the Mexican CNA Water Tax Claims being recorded as discrete items for income tax provision purposes which increased the effective tax rate by 2% over the prior year.
Net Income
Net income for the nine months ended September 30, 2013 was $34.9 million, a decrease of $25.9 million as compared to $60.8 million for the same period in 2012, due to the factors described above.
Segment Reporting
The Company reports its core Specialty Phosphates business separately from GTSP & Other. Specialty Phosphates consists of the products lines Specialty Ingredients, Food & Technical Grade PPA and STPP & Detergent Grade PPA. Kelatron, AMT and Triarco are included in the Specialty Phosphates US & Canada segment and in the Specialty Ingredients product line. GTSP & Other includes fertilizer co-product GTSP and other non-Specialty Phosphate products. The primary performance indicators for the chief operating decision maker are sales and operating income. The following table sets forth the historical results of these indicators by segment:
 
 
Three Months Ended
 
 
 
September 30,
2013
 
September 30,
2012
 
Net Sales % Change
Segment Net Sales
 
 
 
 
 
Specialty Phosphates US & Canada
$
153,588

 
$
144,664

 
6.2
 %
Specialty Phosphates Mexico
44,712

 
41,222

 
8.5
 %
Total Specialty Phosphates
198,300

 
185,886

 
6.7
 %
GTSP & Other
21,693

 
25,302

 
(14.3
)%
Total
$
219,993

 
$
211,188

 
4.2
 %
 
 
 
 
 
 
Segment Operating Income
 
 
 
 
 
Specialty Phosphates US & Canada
$
21,482

 
$
22,759

 
 
Specialty Phosphates Mexico
2,964

 
2,369

 
 
Total Specialty Phosphates
24,446

 
25,128

 
 
GTSP & Other
(3,725
)
 
(542
)
 
 
Total
$
20,721

 
$
24,586

 
 
 
 
 
 
 
 
Segment Operating Income % of net sales
 
 
 
 
 
Specialty Phosphates US & Canada
14.0
 %
 
15.7
 %
 
 
Specialty Phosphates Mexico
6.6
 %
 
5.7
 %
 
 
Total Specialty Phosphates
12.3
 %
 
13.5
 %
 
 
GTSP & Other
(17.2
)%
 
(2.1
)%
 
 
Total
9.4
 %
 
11.6
 %
 
 
 
 
 
 
 
 
Depreciation and amortization expense
 
 
 
 
 
Specialty Phosphates US & Canada
$
6,967

 
$
5,732

 
 
Specialty Phosphates Mexico
1,740

 
3,670

 
 
Total Specialty Phosphates
$
8,707

 
9,402

 
 
GTSP & Other
236

 
1,160

 
 
Total
$
8,943

 
$
10,562

 
 



Page 28 of 37



Table of Contents


 
Nine Months Ended
 
 
 
September 30,
2013
 
September 30,
2012
 
Net Sales % Change
Segment Net Sales
 
 
 
 
 
Specialty Phosphates US & Canada
$
463,633

 
$
432,528

 
7.2
 %
Specialty Phosphates Mexico
126,997

 
139,951

 
(9.3
)%
Total Specialty Phosphates
590,630

 
572,479

 
3.2
 %
GTSP & Other
56,980

 
81,141

 
(29.8
)%
Total
$
647,610

 
$
653,620

 
(0.9
)%
 
 
 
 
 
 
Segment Operating Income
 
 
 
 
 
Specialty Phosphates US & Canada
$
56,032

 
$
70,262

 
 
Specialty Phosphates Mexico
4,954

 
17,156

 
 
Total Specialty Phosphates
60,986

 
87,418

 
 
GTSP & Other (a) (b)
(210
)
 
1,590

 
 
Total
$
60,776

 
$
89,008

 
 
 
 
 
 
 
 
Segment Operating Income % of net sales
 
 
 
 
 
Specialty Phosphates US & Canada
12.1
 %
 
16.2
%
 
 
Specialty Phosphates Mexico
3.9
 %
 
12.3
%
 
 
Total Specialty Phosphates
10.3
 %
 
15.3
%
 
 
GTSP & Other (a) (b)
(0.4
)%
 
2.0
%
 
 
Total
9.4
 %
 
13.6
%
 
 
 
 
 
 
 
 
Depreciation and amortization expense
 
 
 
 
 
Specialty Phosphates US & Canada
$
20,540

 
$
17,280

 
 
Specialty Phosphates Mexico
5,815

 
11,233

 
 
Total Specialty Phosphates
$
26,355

 
28,513

 
 
GTSP & Other
1,439

 
3,605

 
 
Total
$
27,794

 
$
32,118

 
 

(a)
The nine month period ended September 30, 2013 includes a $7.2 million benefit to earnings for the settlement of the Mexican CNA Water Tax Claims and a $2.3 million charge to earnings for out of period costs in the US.
(b)
The nine month period ended September 30, 2012 includes a $7.1 million benefit to earnings primarily for the settlement with Rhodia on their liability for the charges to be paid to the CNA for the Mexican CNA Water Tax Claims and a $2.4 million charge to earnings for out of period costs in Mexico.


Page 29 of 37



Table of Contents

Three months ended September 30, 2013 compared to the three months ended September 30, 2012
Segment Net Sales:
Specialty Phosphates US & Canada net sales increased 6.2% for the three months ended September 30, 2013 when compared with the same period in 2012. Volumes increased 7.7% due to a benefit of 5.3% from the AMT and Triarco acquisitions and 2.4% growth from the core business, due to success on geographical expansion and product innovation growth strategies, while average selling prices decreased by 1.5% due primarily to sales mix.
Specialty Phosphates Mexico net sales increased 8.5% for the three months ended September 30, 2013 when compared with the same period in 2012. Volumes increased 5.2% as a result of improved operations and selling prices increased 3.3%.
GTSP & Other net sales decreased 14.3% for the three months ended September 30, 2013 when compared with the same period in 2012. Volumes decreased 3.3% and selling prices decreased 11.0% under weak fertilizer market conditions with prices ending 15-20% below where the quarter began.
Segment Operating Income Percentage of Net Sales:
The 170 basis point decrease in Specialty Phosphates US & Canada for the three months ended September 30, 2013 compared with the same period in 2012 is due to lower average selling prices which decreased margins by 130 basis points, increased raw material costs which decreased margins 100 basis points, higher depreciation in the core business which decreased margins by 40 basis points, and higher fixed costs which decreased margins 20 basis points, partially offset by increased volumes that added 120 basis points.
The 90 point increase in Specialty Phosphates Mexico for the three months ended September 30, 2013 compared with the same period in 2012 is due to higher selling prices which increased margins by 290 basis points, higher sales volumes which increased margins by 420 basis points, lower raw material costs which increased margins by 110 basis points, and lower depreciation which increased margins by 470 basis points. Higher fixed costs decreased margins by 590 basis points and increased turnaround cost at our Coatzacoalcos manufacturing facility decreased margins by 610 basis points.
The 1,500 basis point decrease in GTSP & Other for the three months ended September 30, 2013 compared with the same period in 2012 is due to lower selling prices which decreased margins 1,270 basis points, a lower of cost or market reserve which decreased margins by 630 basis points, higher fixed costs which lowered margins 420 basis points, lower sales volumes which decreased margins by 40 basis points, and increased turnaround cost at our Coatzacoalcos manufacturing facility which decreased margins by 320 basis points. Lower raw material cost increased margins by 810 basis points and lower depreciation increased margins by 370 basis points.
Raw material cost effects for the Company overall were insignificant when compared against the prior period.
Nine months ended September 30, 2013 compared to the nine months ended September 30, 2012
Segment Net Sales:
Specialty Phosphates US & Canada net sales increased 7.2% for the nine months ended September 30, 2013 when compared with the same period in 2012. Volumes increased 8.3% due to a benefit of 6.5% from the AMT and Triarco acquisitions and 1.8% growth from the core business, due to success on geographical expansion and product innovation growth strategies. Selling prices decreased by 1.1% due primarily to sales mix.
Specialty Phosphates Mexico net sales decreased 9.3% for the nine months ended September 30, 2013 when compared with the same period in 2012. Volumes decreased 7.3% as the business experienced operating issues in the first half of 2013 which limited production and sales. Selling prices decreased 2.0% primarily from a price reset upon the renewal of a long term contract and declines in the less differentiated detergent grade products.
GTSP & Other net sales decreased 29.8% for the nine months ended September 30, 2013 when compared with the same period in 2012. Volumes decreased 24.2% and selling prices decreased 5.6% due to weak fertilizer market demand which resulted in a sharp decline in third quarter 2013 market selling prices that decreased 15-20% within the quarter.
Segment Operating Income Percentage of Net Sales:
The 410 basis point decrease in Specialty Phosphates US & Canada for the nine months ended September 30, 2013 compared with the same period in 2012 is primarily due to increased costs of goods sold in 2013 compared to an inventory lag benefit in the first quarter 2012 which decreased margins by 360 basis points, elevated cost of goods sold in the first quarter 2013 for revisions in inventory accounting estimates, an out of period adjustment related to a long term supply agreement,

Page 30 of 37



Table of Contents

demurrage on raw material purchases and acquisition accounting expenses which decreased margins by 130 basis points, lower selling prices which decreased margins by 90 basis points, and higher fixed costs in the core business which decreased margins by 50 basis points. Higher volumes increased margins by 220 basis points.
The 840 basis point decrease in Specialty Phosphates Mexico for the nine months ended September 30, 2013 compared with the same period in 2012 is primarily due to higher cost of goods sold for first half 2013 manufacturing issues and a revision of estimates for phosphate rock inventories which decreased margins by 540 basis points, lower selling prices which decreased margins by 180 basis points, lower sales volume which decreased margins by 190 basis points, increased fixed costs which decreased margins by 610 basis points, and increased turnaround cost at our Coatzacoalcos manufacturing facility decreased margins by 180 basis points. Lower raw material costs increased margins by 470 basis points and lower depreciation increased margins by 390 basis points.
The 240 basis point decrease in GTSP & Other for the nine months ended September 30, 2013 compared with the same period in 2012 is primarily due to lower selling prices which decreased margin by 580 basis points, a lower of cost or market reserve which decreased margins by 200 basis points, lower sales volumes which decreased margins by 290 basis points, and increased turnaround cost at our Coatzacoalcos manufacturing facility decreased margins by 100 basis points. Lower raw material costs, mainly from lower rock and sulfur market prices, increased margins by 540 basis points, lower depreciation added 270 basis points, and lower fixed costs which increased margins by 120 basis points.

Liquidity and Capital Resources
The following table sets forth a summary of the Company’s cash flows for the periods indicated.
 
(Dollars in millions)
Nine months ended
 
September 30,
2013
 
September 30,
2012
Operating Activities
$
74.0

 
$
100.8

Investing Activities
(30.3
)
 
(43.1
)
Financing Activities
(34.7
)
 
(56.4
)

Nine months ended September 30, 2013 compared to nine months ended September 30, 2012
Net cash provided by operating activities was $74.0 million for the nine months ended September 30, 2013 as compared to $100.8 million for 2012, a decrease of $26.8 million. The decrease in operating activities cash resulted from unfavorable changes of $25.9 million in net income as described earlier, $1.7 million in working capital and $3.7 million in non-cash adjustments to income, partially offset by a favorable change of $4.5 million in other long term assets and liabilities.
The unfavorable change in working capital is derived from it being a source of cash of $7.8 million in 2013 compared to a source in 2012 of $9.5 million, a decrease in cash of $1.7 million. Collections improved on the backlog of value added tax, or VAT, refunds due the Company from the Mexican government; however, this was offset by less cash generation from inventory movements due to increased requirements in Mexico to support improved production performance. Accounts receivable was a $5.2 million use of cash in 2013 compared to a $11.3 million source of cash in 2012, but remained at a consistent trend as a percent of quarterly sales, when adjusted for GTSP open accounts receivable of $1.0 million, $1.6 million, $15.3 million and $4.3 million as of September 30, 2013, June 30, 2013, March 31, 2013 and December 31, 2012, respectively. Subsequent to the balance sheet date, on October 1, 2013 our Mexican subsidiary received their 2012 income tax refund of approximately $8.7 million.
Net cash used for investing activities was $30.3 million for the nine months ended September 30, 2013, compared to $43.1 million for 2012, a decrease in spending of $12.8 million. The change is mainly due to $14.0 million higher capital spending at our Coatzacoalcos, Mexico manufacturing facility as we continue to make investments to improve the reliability and flexibility of that operation. In the third quarter of 2012 the AMT business was acquired for $27.1 million.
Management projects total capital expenditures to be near the high end of the $35-40 million expectation for 2013, and in the $45-50 million range for 2014. The maintenance portion of these capital expenditures is expected to be at the high end of typical $20-$25 million range in 2013, and expected to exceed the high end of the typical range in 2014 by $5-$10 million, before returning to the typical range. Investment continues to be focused on capacity enhancements for US, Canada and Mexico Specialty Ingredients facilities, and further enhancing Mexico's reliability and efficiency, as well as it's flexibility, to process multiple grades of phosphate rock, consistent with the Company's supply chain diversification strategy. A new higher-

Page 31 of 37



Table of Contents

grade PPA operation was successfully commissioned in the third quarter 2013 as part of the long term plant upgrade program for Coatzacoalcos. This higher-grade PPA will further support internal needs for the US and Canada network and allow a continued upgrading of the product mix in the Latin America region.
Innophos currently estimates that full exploration costs to a proven reserves standard for its Baja California mining concessions could require expenditures of $10 to $15 million over a period, currently estimated at three to five years, inclusive of expenditures to date. This estimate includes mineral rights payments, taxes, mineral resource measurement, beneficiation process design and completion of feasibility studies. Full expenditures would only occur if interim milestone goals were successfully attained. Combined 2010 through 2012 expenditures on the exploration of the Baja California Sur concession deposits were approximately $3.1 million, and management currently expects to spend at a similar annual trend rate in 2013. Spending could increase in 2014 by up to $3 million above the previous annual trend rate to accelerate evaluations of the Santo Domingo concession. Innophos intends to seek one or more partners for these efforts, but anticipates no difficulties in completing the exploration phase without a partnership.
Net cash from financing activities for the nine months ended September 30, 2013, was a use of $34.7 million, compared to a use of $56.4 million in 2012, a decrease in the use of cash of $21.7 million. This was mainly due to $13.0 million increased loan borrowings, $8.0 million lower loan repayments, $7.2 million lower common stock repurchases, partially offset by $5.8 million higher dividend payments and $0.7 million lower excess tax benefits from exercise of stock options.
In April 2013, the Company paid $4.4 million to settle the Mexican CNA Water Tax Claims under an amnesty program governed by the Mexican government.
Innophos and its subsidiaries and affiliates may from time to time seek to acquire or otherwise retire outstanding debt through privately negotiated transactions, exchanges or otherwise. Debt repurchases or exchanges, if any, will depend on prevailing market conditions, Company liquidity requirements, restrictive financial covenants and other factors applicable at the time. The amounts involved may be material.
On September 30, 2013, the Company had cash and cash equivalents outside the United States of $22.2 million, or 62% of the Company's balance. Further, the foreign cash amounts are not restricted by law to be used in other countries. Our current operating plan does not include repatriation of any of the cash and cash equivalents held outside the United States to fund the United States operations. However, in the event we do repatriate cash and cash equivalents held outside of the United States, we may be required to accrue and pay United States income taxes to repatriate these funds.
The Company's available financial resources allow for the continuation of dividend payments, pursuit of several “bolt-on” acquisition projects and further geographic expansion initiatives. We further believe that on-hand cash combined with cash generated from operations, including our Mexican operations, and availability under our revolving line of credit, will be sufficient to meet our obligations such as debt service, tax payments, capital expenditures and working capital requirements for at least the next twelve months. We expect to fund all these obligations through our existing cash and our future operating cash flows. However, future operating performance for the Company is subject to prevailing economic and competitive conditions and various other factors that are uncertain. If the cash flows and other capital resources available to the Company, such as its revolving loan facility, are insufficient to fund our debt and other liquidity needs, the Company may have to take alternative actions that differ from current operating plans.
On October 25, 2013 the Company's Board of Directors declared an increase to its quarterly dividend from $0.35 per share to $0.40 per share to be paid in the fourth quarter of 2013.


Critical Accounting Estimates and Policies
There have been no material changes from the critical accounting estimates previously disclosed in our 2012 Annual Report on Form 10-K.
 

Page 32 of 37



Table of Contents

ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to certain market risks as part of our ongoing business operations. Primary exposures include changes in interest rates, as borrowings under our Loan Agreement will bear interest at floating rates based on LIBOR plus an applicable borrowing margin. We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status. For fixed-rate debt, interest rate changes do not affect earnings or cash flows. Conversely, for floating-rate debt, interest rate changes generally affect our earnings and cash flows, assuming other factors are held constant.
At September 30, 2013, we had $97 million principal amount of variable-rate debt and a $225.0 million revolving credit facility, of which $65.0 million was outstanding, both of which approximate fair value (determined using level 2 inputs within the fair value hierarchy). Total remaining availability was $157.7 million, taking into account $2.3 million in face amount of letters of credit issued under the sub-facility. Simultaneously with initiating the new senior facility, Innophos entered into an interest rate swap, swapping the LIBOR exposure on $100.0 million of floating rate debt with a fixed rate of 0.9475% plus the applicable margin on the debt expiring in December 2017. This interest rate swap has been designated as a cashflow hedge with the changes in value recorded through other comprehensive income. The fair value of this interest rate swap is an asset of approximately 0.8 million (determined using level 2 inputs within the fair value hierarchy) as of September 30, 2013.
Changes in economic conditions could result in higher interest rates, thereby increasing our interest expense on our revolving line of credit. Changes in economic conditions may also result in lower operating income, reducing our funds available for capital investment, operations or other purposes. In addition, a substantial portion of our cash flow has been used to service debt and fund working capital needs, which may affect our ability to make future acquisitions or capital expenditures. We may from time to time use interest rate protection agreements to minimize our exposure to interest rate fluctuation. Regardless of hedges, we may experience economic loss and a negative impact on earnings or net assets as a result of interest rate fluctuations. Based on $65.0 million outstanding borrowings as floating rate debt (not included in the swap) under our revolving credit facility, an immediate increase of one percentage point would cause an increase to interest expense of approximately $0.7 million per year.
From time to time, we may enter into longer term natural gas supply contracts in an effort to eliminate some of the volatility in our energy costs. Our natural gas spending for 2013 is estimated to be less than 3% of cost of goods sold.
We do not currently hedge our currency rate risks.
We believe that our concentration of credit risk related to trade accounts receivable is limited since these receivables are spread among a number of customers and are geographically dispersed. No customer accounted for more than 10% of our sales in the last 3 years.
Foreign Currency Exchange Rates
The U.S. Dollar is the functional currency of the Canadian and Mexican operations. Accordingly, these operations’ monetary assets and liabilities are translated at current exchange rates, non-monetary assets and liabilities are translated at historical exchange rates, and revenue and expenses are translated at average exchange rates and at historical exchange rates for the related revenue and expenses of non-monetary assets and liabilities. All transaction gains and losses are included in net income.
Our principal source of exchange rate exposure in our foreign operations consists of expenses, such as labor expenses, which are denominated in the foreign currency of the country in which we operate. A decline in the value of the U.S. Dollar relative to the local currency would generally cause our operational expenses (particularly labor costs) to increase (conversely, a decline in the value of the foreign currency relative to the U.S. Dollar would cause these expenses to decrease). We believe that normal exchange rate fluctuations consistent with recent historical trends would have a modest impact on our expenses, and would not materially affect our financial condition or results of operations. Nearly all of our sales are denominated in U.S. Dollars and our exchange rate exposure in terms of sales revenues is minimal.
Inflation and changing prices
Our costs and expenses will be subject to inflation and price fluctuations. Significant price fluctuations in raw materials, freight, and energy costs, if not compensated for by cost savings from production efficiencies or price increases passed on to customers could have a material effect on our financial condition and results of operations.

Page 33 of 37



Table of Contents


Off-Balance Sheet Arrangements
We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as “structured finance or special purpose entities”, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

ITEM 4.
CONTROLS AND PROCEDURES
Disclosure Control and Procedures
The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) that are designed to provide reasonable assurance that information required to be reported in the Company's consolidated financial statements and filings is recorded, processed, summarized and reported within the periods specified in the rules and forms of the Securities and Exchange Commission, or SEC, and that such information is accumulated and communicated to the Company's management, including its Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.
As of September 30, 2013 the Company completed an evaluation under the supervision and with the participation of the Company's management, including the Company's Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based upon that evaluation, the Principal Executive Officer and Principal Financial Officer concluded that the Company's disclosure controls and procedures are effective at the reasonable assurance level.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting during or with respect to the third quarter of 2013 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.


Page 34 of 37



Table of Contents

PART II
 
ITEM 1.
LEGAL PROCEEDINGS
Note 13 of Notes to Consolidated Condensed Financial Statements in “Item 1. Financial Statements" contained in this Quarterly Report on Form 10-Q is incorporated herein by reference.
 
ITEM 1A.
RISK FACTORS
There have been no material changes from the risk factors previously disclosed in our 2012 Annual Report on Form 10-K.
ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3.
DEFAULTS UPON SENIOR SECURITIES
None.

ITEM 4.
MINE SAFETY DISCLOSURES
None.

ITEM 5.
OTHER INFORMATION
None.

ITEM 6.
EXHIBITS
a) Exhibits. The following exhibits are filed or furnished as part of this report:
Exhibit No.
 
Description
31.1
 
Certification of Principal Executive Officer dated October 30, 2013 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2
 
Certification of Principal Financial Officer dated October 30, 2013 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*
 
Certification of Principal Executive Officer dated October 30, 2013 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*
 
Certification of Principal Financial Officer dated October 30, 2013 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
*
Not to be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liability of that section, nor deemed to be incorporated by reference into any filing under that Act or the Securities Act of 1933.


Page 35 of 37



Table of Contents

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
INNOPHOS HOLDINGS, INC.
 
 
 
/s/ Randolph Gress
By:
Randolph Gress
Its:
Chief Executive Officer and Director
 
(Principal Executive Officer)
 
Dated:
October 30, 2013
 
INNOPHOS HOLDINGS, INC.
 
 
 
/s/ Mark Feuerbach
By:
Mark Feuerbach
Its:
Vice President and Chief Financial Officer
 
(Principal Financial Officer)
 
Dated:
October 30, 2013


Page 36 of 37



Table of Contents

EXHIBIT INDEX
Exhibit No.
  
Description
31.1
  
Certification of Principal Executive Officer dated October 30, 2013 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2
  
Certification of Principal Financial Officer dated October 30, 2013 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1
  
Certification of Principal Executive Officer dated October 30, 2013 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2
  
Certification of Principal Financial Officer dated October 30, 2013 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002



Page 37 of 37